Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis - 02/10/14
Abstract |
I review how diverse inherited and acquired abnormalities in epidermal structural and enzymatic proteins converge to produce defective permeability barrier function and antimicrobial defense in patients with atopic dermatitis (AD). Although best known are mutations in filaggrin (FLG), mutations in other member of the fused S-100 family of proteins (ie, hornerin [hrn] and filaggrin 2 [flg-2]); the cornified envelope precursor (ie, SPRR3); mattrin, which is encoded by TMEM79 and regulates the assembly of lamellar bodies; SPINK5, which encodes the serine protease inhibitor lymphoepithelial Kazal-type trypsin inhibitor type 1; and the fatty acid transporter fatty acid transport protein 4 have all been linked to AD. Yet these abnormalities often only predispose to AD; additional acquired stressors that further compromise barrier function, such as psychological stress, low ambient humidity, or high-pH surfactants, often are required to trigger disease. TH2 cytokines can also compromise barrier function by downregulating expression of multiple epidermal structural proteins, lipid synthetic enzymes, and antimicrobial peptides. All of these inherited and acquired abnormalities converge on the lamellar body secretory system, producing abnormalities in lipid composition, secretion, and/or extracellular lamellar membrane organization, as well as antimicrobial defense. Finally, I briefly review therapeutic options that address this new pathogenic paradigm.
Le texte complet de cet article est disponible en PDF.Key words : Antimicrobial peptides, atopic dermatitis, barrier function, ceramides, cytokines, filaggrin, kallikreins, lamellar bodies, lipid composition, pH, serine protease inhibitors, TH2 cells
Abbreviations used : AD, CE, FFA, FLG, GC, IV, KLK, LEKTI, NS, PAR2, PS, SC, SP, TJ
Plan
Series editors: Joshua A. Boyce, MD, Fred Finkelman, MD, and William T. Shearer, MD, PhD |
|
Supported by National Institutes of Health grant AR019098 and by the Medical Research Service, Department of Veterans Affairs. These contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institute of Arthritis and Musculoskeletal and Skin Diseases or NIH. |
|
Disclosure of potential conflict of interest: P. M. Elias has received research support from the National Institutes of Health, has a board membership with Symrise, has consultant arrangements with Cote Orphan Consulting and the Federal Trade Commission, has a patent for Epiceram with the University of California, and receives royalties from the University of California for Epiceram. J. S. Wakefield declares that she has no relevant conflicts of interest. |
|
Terms in boldface and italics are defined in the glossary on page 782. |
Vol 134 - N° 4
P. 781 - octobre 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?